Annovis Bio, Inc. logo

Annovis Bio, Inc.

NYSE:ANVS

Overview | Financials
Company Name Annovis Bio, Inc.
Symbol ANVS
Currency USD
Price 4.37
Market Cap 60,293,764
Dividend Yield 0%
52-week-range 4.31 - 22.49
Industry Biotechnology
Sector Healthcare
CEO Dr. Maria L. Maccecchini Ph.D.
Website https://www.annovisbio.com

An error occurred while fetching data.

About Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's

Related Stocks

Sonendo, Inc. logo

Sonendo, Inc.

SONX

1.92 USD

Vapotherm, Inc. logo

Vapotherm, Inc.

VAPO

2.17 USD

Rafael Holdings, Inc. logo

Rafael Holdings, Inc.

RFL

1.95 USD

Enzo Biochem, Inc. logo

Enzo Biochem, Inc.

ENZ

0.763 USD

Ambrx Biopharma Inc. logo

Ambrx Biopharma Inc.

AMAM

28 USD

Financials

Numbers are in millions USD

Numbers are in millions USD